Skip to main content

Gene Logic Signs on IDEC Pharmaceuticals as Database Subscriber

NEW YORK, Jan 8 – Gene Logic has signed on IDEC pharmaceuticals, a developer of antibody therapeutics, as a multi-year subscriber to its GeneExpress Oncology DataSuite, Gene Logic announced Monday.

IDEC will use the database to discover and develop cancer therapeutics. The database provides disease-specific gene expression profiles for a number of human cancer types . The system will be deployed, along with Gene Logic’s GX2000 software, throughout the company’s R&D unit.

Financial terms of the subscription agreement were not disclosed.

“We are very pleased to establish a partnership with IDEC Pharmaceuticals to support their focused research on cancer," Gene Logic CEO Mark Gessler said in a statement. " This partnership strengthens and further validates our ongoing strategy of delivering targeted solutions that address the specialized needs of our pharmaceutical and biotechnology customers as they pursue genomics-driven drug development initiatives."

Gene Logic has recently signed as subscribers to its databases Organon, Boehringer Ingelheim Pharmaceuticals, Biogen, Proctor & Gamble,

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.